Price$75.37-42.86 (-36.25%)
2026-04-212026-07-24
News · 26 weeks120+250%
2026-02-012026-07-26
Mix3490d
- Insider18(53%)
- Other7(21%)
- SEC Filings5(15%)
- Earnings2(6%)
- Dividends1(3%)
- Analyst1(3%)
Latest news
25 items- PRZoetis Launches Portela® (relfovetmab) in Canada and the European UnionFirst long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. Backed by nearly a decade of science and research, Portela demonstrated effectiveness in alleviating OA pain in a pivotal nine-month European field study with improvements observed from a
- PRZoetis Launches Lenivia® (izenivetmab injection) in Canada and the European UnionUp to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection Zoetis Inc. (NYSE:ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study, with effects observed from as early as Day 7 aft
- INSIDERSEC Form 4 filed by Executive Vice President Sarbaugh Keith4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Peck Kristin C4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Esch Kevin4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Nayak Abhay U4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Driscoll Rimma4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Fuller Julie4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Lagano Roxanne4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Ferran Astorga Jeannette4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Joseph Wetteny4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Nayak Abhay U3/A - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic CapabilitiesAcquisition would strengthen Zoetis’ Global Diagnostics portfolio through teleradiology, imaging services, and workflow technology, advancing a more comprehensive end-to-end Virtual Reference Lab Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisition adds around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. Integrating VitalRADS’ capabilities into Zoetis’ Global Diagnostics portfolio enhances Zoetis’ reference laboratory services, delivering AI-assisted report generation and quali
- PRZoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-NDRecombinant vector vaccine protects chickens against Newcastle disease and Marek's disease in a single dose Zoetis Inc. (NYSE:ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease (ND) and Marek’s disease viruses. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both diseases with a single dose. Newcastle disease is a notifiable disease under EU animal health regulations and a significant cause of mortality and production losses in commercial poultry, as evidenced by rece
- PRZoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial ResultsZoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, August 6, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on August 6, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to
- INSIDERSEC Form 4 filed by Director Stetter Mark4 - Zoetis Inc. (0001555280) (Issuer)
- SECSEC Form 11-K filed by Zoetis Inc.11-K - Zoetis Inc. (0001555280) (Filer)
- INSIDERNew insider Nayak Abhay U claimed no ownership of stock in the company (SEC Form 3)3 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better FutureAchieved initial targets set in 2021 across Communities, Animals and Planet $35 million in grants disbursed by the Zoetis Foundation from 2021-2025 Received regulatory approvals for innovative vaccines and therapies, including science-driven solutions to address avian influenza in poultry and dairy cattle Reduced Scope 1 and 2 emissions by 29% since 2021, sourcing 85% of global electricity from renewable sources1 Zoetis published its 2025 Sustainability Report, highlighting progress achieved in 2025 through its Driven to Care strategy. This report marks a significant milestone as Zoetis delivers on its initial aspirations set in 2021 and introduces its next phase with renewed f
- SECSEC Form SD filed by Zoetis Inc.SD - Zoetis Inc. (0001555280) (Filer)
- ANALYSTZoetis downgraded by ArgusArgus downgraded Zoetis from Buy to Hold
- INSIDERDirector Stetter Mark converted options into 1,572 shares (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- SECZoetis Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Zoetis Inc. (0001555280) (Filer)
- INSIDERDirector Parent Louise M converted options into 12,130 shares, increasing direct ownership by 75% to 28,394 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis to Participate in Upcoming Investor ConferencesZoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor conferences. Stifel 2026 Jaws & Paws Conference on Thursday, May 28, 2026 at 3:00 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 1:20 p.m. CT Interested parties can access the live audio webcasts of the presentations by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of each event. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing ca
ZTS FAQ
8 questionsWhat does Zoetis Inc. do?
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria...Where does ZTS stock trade?
Zoetis Inc. (ZTS) is listed on NYSE.What sector and industry is ZTS in?
Zoetis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zoetis Inc. go public?
Zoetis Inc. (ZTS) completed its IPO in 2013.Does ZTS pay a dividend?
ZTS's most recent ex-dividend date was 2026-07-20 with a cash dividend of $0.53 per share. No future ex-date is on file yet.What are analysts saying about ZTS?
Zoetis Inc. has had 8 recent analyst actions on file. The most recent action was from Argus: Hold on 2026-05-27.What companies are similar to ZTS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZTS side-by-side with any of them on Quantisnow.How can I track ZTS on Quantisnow?
Quantisnow aggregates Zoetis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZTS to receive live email and push alerts on every new disclosure.